Advertisement

  

U.S. News

FDA Panel Rules Against NeurogesX Patch for HIV-Related Neuropathy

From U.S. Centers for Disease Control and Prevention

February 15, 2012

A Food and Drug Administration panel of outside experts has ruled against using a product derived from chili peppers to treat neuropathic pain in people with HIV. The committee voted 12-0 that clinical data do not show substantial evidence that NeurogesX Inc.'s Qutenza is effective against pain in the extremities suffered by many HIV patients. The experts also voted 11-0, with one abstention, that the capsaicin patch's risk-benefit profile was not acceptable for use by persons with HIV.

Back to other news for February 2012

Adapted from:
Reuters
02.09.2012; David Morgan




  
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
 
See Also
FDA Pain Patch Decision: Making a "Sophie's Choice" With People's Lives (on HIVandHepatitis.com)
No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement
Advertisement